Eckert & Ziegler Stock EUZ.DE
Eckert & Ziegler stock (EUZ.DE): Quarterly and annual results since 2023 from Quarterly Report and IR documents: revenue, earnings, balance sheet, cash flow and management guidance, every figure with its source. As of 08/2026, quarterly reporting. Stock analysis by NadirAlpha. Revenue Q2 2026: EUR 76 million (-5% year on year). Latest reported (Q2 2026): Equity ratio, Pre-tax profit margin. Latest reading: Revenue decelerating, New market.
Revenue decelerating strategy: New market
The new quarter, monitored by AI. · NadirAlpha follows every stock through its original filings: the latest figures against their history, guidance against actuals; neutral, continuously updated, every figure clickable with its source.
AI-generated report · not investment advice · figures extracted automatically; please verify against the linked original more
AI-generatedCreated with AI assistance from the company's linked original filings (transparency per Art. 50 EU AI Act). More about the tool: Claude Code.
Not investment adviceNeutral financial information, no recommendation, no investment research within the meaning of MiFID II.
Verify yourselfFigures are extracted automatically, errors are possible. Every figure is clickable with its source; the issuer's original documents are always authoritative.
EditorialThe texts (business model, current status, development and others) are written AI-editorially from the original reports alone, cross-checked automatically and backed with sources; the company's own account, no assessment of our own. Methodology
AI research · This page works as a source-backed data basis for further research with AI assistants such as Claude; every figure remains verifiable via the source links.
Advertisement
Business Model#
What the company does and how it earns its money; written AI-editorially, exclusively from the company's original reports, without any assessment of our own. Methodology
Eckert & Ziegler SE is a German specialty company operating in the nuclear medicine and radiation technology sector. It develops, produces, and distributes radioactive components and equipment for medical, scientific, and industrial applications, with core business lines spanning radiopharma (including therapeutic radioisotopes such as Lutetium-177 and Ruthenium-106), medical radiation therapy products, and isotope products for calibration and industrial use. The company serves hospitals, pharmaceutical manufacturers, research institutions, and industrial customers worldwide, and additionally offers contract development and manufacturing services (CDMO) to third parties in the radiopharmaceutical space.
Advertisement
Current Status#
Summary of the most recent reporting period: core figures, drivers and management statements; written editorially from the current original report, every figure backed by a source number. Methodology
Assessment by NadirAlpha, as of Q2 2026.
Eckert & Ziegler reported second-quarter 2026 revenue of 76.4 million euros, net income of 12.1 million euros, and diluted EPS of 0.58 euros 114. Lutetium-177 revenues more than tripled and Contract Development and Manufacturing (CDMO) revenues nearly doubled year on year during the period 14. The company opened a medical isotope production facility in China, deepened its partnership with Thor Medical for Lead-212-based therapies, and received MDR certification for Ruthenium-106 eye applicators 14. The dividend for fiscal year 2025 was raised to 0.22 euros per share 14.
Management commentary on the FY2025 results (IR-Annual, 2026-03-23):
“The new laboratory building for future generators in Berlin celebrated its topping-out ceremony.” Dr. Harald Hasselmann, Vorsitzender des Vorstands 12 (translation, original on hover)
“In the Czech Republic, we were able to successfully scale the production of the therapeutic radioisotope Actinium-225 in order to expand our isotope portfolio.” Dr. Harald Hasselmann, Vorsitzender des Vorstands 12 (translation, original on hover)
Revenue · 2026-Q276€m−5.2 % vs. 2025-Q2
Net profit · 2026-Q212€m+1.7 % vs. 2025-Q2
EPS · 2026-Q20.58€+3.6 % vs. 2025-Q2
Revenue trend
Guidance
For FY2026, the company guides Revenue ~320 €m (raised); EBITDA (adjusted) ~80 €m (raised). 14
ProfitabilityOperating income in 2026-Q2 was 17.4 million euros and net income reached 12.1 million euros, with diluted EPS of 0.58 euros 114. Free cash flow for the quarter was 3.4 million euros after capital expenditures of 4.2 million euros 114. Income from equity-accounted associates rose by 31.6% to 0.4 million euros in the period, driven primarily by positive valuation effects at the Qi Kang Medical stake 14.
LeverageAt the end of 2026-Q2, the company held cash of 110.2 million euros, resulting in a net cash position of 99.8 million euros 114. No net-debt/EBITDA (LTM) ratio is reported in the available disclosures. The cash balance was lower than at the close of 2026-Q1 (123.8 million euros), while the company remained in an overall net cash position.
Management viewThe company deepened its partnership with Thor Medical for the development of Lead-212 (Pb-212)-based therapies, strengthening its pipeline in targeted alpha therapy 14. Eckert & Ziegler obtained MDR certification for its Ruthenium-106 eye applicators for the treatment of ocular tumors, broadening the regulatory pathway for this product in European markets 14. The dividend for fiscal year 2025 was raised to 0.22 euros per share 14.
ChangeOn a first-half basis, operating cash flow declined by 41.7% to 12.8 million euros year on year, with the company citing the absence of a prior-year payment from Chinese joint venture Qi Kang Medical as the primary reason 14. Second-quarter standalone operating cash flow was 7.6 million euros 114.
Risks (current)Eckert & Ziegler faces a lawsuit by private individuals against the State of Lower Saxony seeking revocation of the handling permit at the Braunschweig facility, with a significant share of the site's output potentially affected 12. Infrastructure recovery costs from a cyberattack in early 2025 continue to burden operations, with effects on the running business and the financial statements noted for the current fiscal year 12. The Pentixapharm Holding AG convertible bond carries a reported derivative accounting risk of 0.4 million euros 10 and potential maximum cash outflows of 9.0 million euros through December 2026 12, while uncertainty from international trade and sanctions policy and the Middle East conflict adds to the broader risk environment 14.
New this reporting periodDuring Q2 2026, Eckert & Ziegler opened a medical isotope production facility in Changzhou/Jintan, China, in cooperation with local partner DongCheng Pharma 14. The facility expands the company's manufacturing presence into the Chinese domestic market for medical isotopes. No other M&A or product launch events dated to Q2 2026 are recorded in the available inputs.
Advertisement
Price & Chart#
Interactive price chart (TradingView) and the trend of key figures from the core tables. Methodology
Daily candles with news and earnings markers. Loads only on click.
Advertisement · affiliate links; we may earn a commissionAffiliate partnerships help us keep these reports free and regularly updated.
Advertisement
Share-Price Drivers#
Factors the company itself names as material for its business development (IR-based); reproduced neutrally, no price forecast and no assessment of our own. Methodology
Expansion of the Medical/radiopharmaceutical business and therapeutic-isotope supply (Actinium-225, Lutetium-177)
Medical is the larger segment and is growing while Isotope Products is softer, so group momentum is increasingly driven by demand for therapeutic radioisotopes and contract manufacturing (13, 12)
Medical is the larger segment and is growing while Isotope Products is softer, so group momentum is increasingly driven by demand for therapeutic radioisotopes and contract manufacturing (13, 12)
Medical segment growth / radioligand-therapy demand
Medical revenue is expanding versus a softer Isotope Products segment, supported by a widening slate of supply and manufacturing agreements (13, 12)
Medical revenue is expanding versus a softer Isotope Products segment, supported by a widening slate of supply and manufacturing agreements (13, 12)
Actinium-225 production ramp and supply contracts
Successful Ac-225 production start (Dec 2024) and Prague production facility, plus multiple supply/licence deals (Telix, Full-Life, Nucleus Radiopharma, GlyTherix, Actinium Pharmaceuticals, Qi Kang JV) point to gaining traction (8, 12)
Successful Ac-225 production start (Dec 2024) and Prague production facility, plus multiple supply/licence deals (Telix, Full-Life, Nucleus Radiopharma, GlyTherix, Actinium Pharmaceuticals, Qi Kang JV) point to gaining traction (8, 12)
Contract manufacturing / CDMO and partnership pipeline
Formation of Eckert & Ziegler CDMO Europe GmbH and framework/manufacturing agreements (Archeus/ART-101, Bicycle Therapeutics, SK Biopharmaceuticals, AtomVie, Pentixapharm) broaden the contract-manufacturing book (11, 12)
Formation of Eckert & Ziegler CDMO Europe GmbH and framework/manufacturing agreements (Archeus/ART-101, Bicycle Therapeutics, SK Biopharmaceuticals, AtomVie, Pentixapharm) broaden the contract-manufacturing book (11, 12)
Capacity expansion / new production sites
New production facilities commissioned, including the Jintan (China) first expansion stage and a medical-isotope site in China, plus the Dresden-Rossendorf building (8, 14)
New production facilities commissioned, including the Jintan (China) first expansion stage and a medical-isotope site in China, plus the Dresden-Rossendorf building (8, 14)
Regulatory approvals for diagnostic products (GalliaPharm)
GalliaPharm 68Ge/68Ga generator received EU approval and market approval in Japan, extending its geographic reach (8, 11)
GalliaPharm 68Ge/68Ga generator received EU approval and market approval in Japan, extending its geographic reach (8, 11)
Isotope Products segment
Isotope Products revenue direction is lower, trailing the faster-growing Medical segment (13)
Isotope Products revenue direction is lower, trailing the faster-growing Medical segment (13)
Profitability and guidance
Reported profitability was higher and full-year guidance was confirmed (114, 112)
Reported profitability was higher and full-year guidance was confirmed (114, 112)
Sector trend: Demand for therapeutic radioisotopes such as Actinium-225 and Lutetium-177 is heading higher, reflected in a growing book of supply and contract-manufacturing agreements and in capacity additions across new production sites (8, 12). Group profitability was higher and guidance confirmed, with the Medical segment utilisation trending up while the older Isotope Products business is softer (13, 114).
Advertisement
Event Timeline#
This timeline collects the material events from the original reports: guidance changes, revenue and margin signals, strategy shifts, product and M&A announcements. Methodology
Overview: one dot per event · click jumps to the period
2026 · 10 events
2026-Q2 · Apr to Jun 2026
New market 2026-08-12
Production site for medical isotopes opened in Changzhou/Jintan, China with DongCheng Pharma 14
Production site for medical isotopes opened in Changzhou/Jintan, China with DongCheng Pharma 14
2026-Q1 · Jan to Mar 2026
Margin expanding 2026-03-23
EBIT margin expanded from 20% to 24%; adjusted EBIT margin from 22% to 25% 12
EBIT margin expanded from 20% to 24%; adjusted EBIT margin from 22% to 25% 12
2025 · 12 events
2025-Q3 · Jul to Sep 2025
“Buy recommendation with a price target of 24.00 €” Berenberg, Analyst 11 (translation, original on hover)
New market 2025-11-12
GalliaPharm® 68Ge/68Ga radionuclide generator received market approval in Japan 11
GalliaPharm® 68Ge/68Ga radionuclide generator received market approval in Japan 11
Strategic pivot 2025-11-12
Capital increase from company funds with 2:1 stock split implemented on 15 August 2025 11
Capital increase from company funds with 2:1 stock split implemented on 15 August 2025 11
2025-Q2 · Apr to Jun 2025
“Wir helfen zu heilen!” Dr. Harald Hasselmann, Vorsitzender des Vorstands 8
Revenue accelerating 2025-08-07
H1 2025 revenue grew 2% to 148.8 million euros; cyberattack-related delivery delays for Gallium generators largely recovered 10
H1 2025 revenue grew 2% to 148.8 million euros; cyberattack-related delivery delays for Gallium generators largely recovered 10
Revenue accelerating 2025-06-05
Full-year group revenue rose 20% to a new company record of 295.9 million EUR 8
Full-year group revenue rose 20% to a new company record of 295.9 million EUR 8
Strategic pivot 2025-06-05
Spin-off of Pentixapharm AG completed 2 October 2024; group refocused on radioisotope core business 8
Spin-off of Pentixapharm AG completed 2 October 2024; group refocused on radioisotope core business 8
New market 2025-06-05
Ac-225 production facility in Czech Republic commenced operations with first production achieved in December 2024 8
Ac-225 production facility in Czech Republic commenced operations with first production achieved in December 2024 8
2025-Q1 · Jan to Mar 2025
Revenue decelerating 2025-05-12
Q1 revenue grew 1% to 68.2 million euros despite a February cyberattack that caused temporary delivery stops for Gallium generators 9
Q1 revenue grew 1% to 68.2 million euros despite a February cyberattack that caused temporary delivery stops for Gallium generators 9
New market 2025-05-12
Ac-225 cyclotron technology license signed with Chinese joint venture Qi Kang Medical; one-time payment of 10 million euros plus royalties 9
Ac-225 cyclotron technology license signed with Chinese joint venture Qi Kang Medical; one-time payment of 10 million euros plus royalties 9
New market 2025-05-12
Strategic partnership established with Bicycle Therapeutics for radioisotope supply and development of Bicycle Radio Conjugates 9
Strategic partnership established with Bicycle Therapeutics for radioisotope supply and development of Bicycle Radio Conjugates 9
2024 · 11 events
2024-Q4 · Oct to Dec 2024
2024-Q3 · Jul to Sep 2024
New market 2024-11-18
European Commission granted approval for Ge-68/Ga-68 radionuclide generator GalliaPharm 15
European Commission granted approval for Ge-68/Ga-68 radionuclide generator GalliaPharm 15
New market 2024-11-18
Multi-year contract signed with Telix Pharmaceuticals Limited for the ProstACT GLOBAL Phase III study 15
Multi-year contract signed with Telix Pharmaceuticals Limited for the ProstACT GLOBAL Phase III study 15
Cash flow inflection 2024-11-18
Operating cash flow reached EUR 27.6 million vs EUR 8.5 million in 2023-Q3 (×3.2). 111
Operating cash flow reached EUR 27.6 million vs EUR 8.5 million in 2023-Q3 (×3.2). 111
2024-Q2 · Apr to Jun 2024
Guidance raised 2024-09-09
FY 2024 EBIT before special items guidance raised to approximately 70 million EUR from approximately 60 million EUR 7
FY 2024 EBIT before special items guidance raised to approximately 70 million EUR from approximately 60 million EUR 7
2024-Q1 · Jan to Mar 2024
“Wir helfen zu heilen” Dr. Harald Hasselmann, Vorstandsvorsitzender 5
Margin compressing 2024-03-19
EBIT margin fell from 21% (2022) to 18% (2023); EBIT of EUR 45.5 million declined 3% despite an 11% revenue increase 5
EBIT margin fell from 21% (2022) to 18% (2023); EBIT of EUR 45.5 million declined 3% despite an 11% revenue increase 5
Divestiture 2024-03-19
Board and supervisory board resolved spin-off of up to 80% of Pentixapharm AG; clinical assets (Pentixapharm AG and Myelo Therapeutics GmbH) classified as discontinued operations under IFRS 5 5
Board and supervisory board resolved spin-off of up to 80% of Pentixapharm AG; clinical assets (Pentixapharm AG and Myelo Therapeutics GmbH) classified as discontinued operations under IFRS 5 5
2023 · 7 events
2023-Q3 · Jul to Sep 2023
Divestiture 2023-11-14
Pentixapharm GmbH converted to AG; supervisory board approved review and preparation of a potential spin-off of up to 100% of Pentixapharm AG 2
Pentixapharm GmbH converted to AG; supervisory board approved review and preparation of a potential spin-off of up to 100% of Pentixapharm AG 2
New market 2023-11-14
Signed ten-year Lu-177 supply agreement with Point BioPharma with total volume exceeding €100 million; reservation agreement with PharmaLogic for carrier-free Ac-225 concluded 2
Signed ten-year Lu-177 supply agreement with Point BioPharma with total volume exceeding €100 million; reservation agreement with PharmaLogic for carrier-free Ac-225 concluded 2
2023-Q2 · Apr to Jun 2023
Margin compressing 2023-08-10
H1 EBITDA fell 10% to €25.6 million and EBIT fell 17% to €19.5 million, driven by higher cost of sales, currency effects and higher interest rates 4
H1 EBITDA fell 10% to €25.6 million and EBIT fell 17% to €19.5 million, driven by higher cost of sales, currency effects and higher interest rates 4
New market 2023-08-10
Signed supply agreement with POINT Biopharma for carrier-free Ac-225 in GMP quality; German authorities granted GMP manufacturing permit for carrier-free Lu-177 4
Signed supply agreement with POINT Biopharma for carrier-free Ac-225 in GMP quality; German authorities granted GMP manufacturing permit for carrier-free Lu-177 4
2023-Q1 · Jan to Mar 2023
Revenue accelerating ◦ 2023-09-19
Q1 revenue rose 16% to EUR 57.9 million, with the Medical segment up 20% and Isotope Products up 13% year on year 3
Q1 revenue rose 16% to EUR 57.9 million, with the Medical segment up 20% and Isotope Products up 13% year on year 3
Strategic pivot 2023-09-19
AGM on 7 June 2023 approved conversion to European SE form; Dr. Andreas Eckert's planned transition from management board to supervisory board announced 3
AGM on 7 June 2023 approved conversion to European SE form; Dr. Andreas Eckert's planned transition from management board to supervisory board announced 3
Advertisement
Key Figures (€m)#
The company's core financial figures in three views, one below the other: fiscal years (as reported; after restatements the table shows the most recent filing version, marked), half-years (6-month basis, H2 = second half on its own) and quarters (3-month basis, not cumulative). All values are extracted automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original. Methodology
All figures serve only to support your own investment decision and are not a recommendation; the company's original reports are authoritative.
Revenue (€m) · annual basis, as reported
Net income (€m) · annual basis, as reported
EPS (€) · annual basis, as reported
Operating cash flow (€m) · annual basis, as reported
Revenue (€m) · quarterly basis, as reported
Net income (€m) · quarterly basis, as reported
EPS (€) · quarterly basis, as reported
Operating cash flow (€m) · quarterly basis, as reported
Cash (€m) · annual basis, as reported
Debt (€m) · annual basis, as reported
Net Debt (€m) · annual basis, as reported
Capex (€m) · annual basis, as reported
FCF (€m) · annual basis, as reported
Cash (€m) · quarterly basis, as reported
Debt (€m) · quarterly basis, as reported
Net Debt (€m) · quarterly basis, as reported
Capex (€m) · quarterly basis, as reported
FCF (€m) · quarterly basis, as reported
Shown: the most recent fiscal years. Full history since FY2022 is on record.
Fiscal years
Amounts in €m · EPS in € per share · as reported
| Period | Revenue | Op. income | Net income | EPS (€) | OCF | Source |
|---|---|---|---|---|---|---|
| FY2025 | 312° | 76.1~ | 48.8° | 0.78 | 58.4° | 112 |
| FY2024 | 295.9 | 61.1 | 33.3° | 0.53 | 66.6° | 8 |
| FY2023 | 246.1 | 45.5EBIT | 26.3° | 1.26° | 47.4° | 1 |
Quarters
Amounts in €m · EPS in € per share · as reported
| Period | Published | Revenue | Op. income | Net income | EPS (€) | FCF | Cash | Net Debt | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2026-Q2* | 2026-08-12 | 76.4 | 17.4 | 12.1 | 0.58*≈ | 3.4 | 110.2 | -99.8 | 114 |
| 2026-Q1* | 2026-05-11 | 72.9 | 16 | 10.4 | 0.17 | -0.4 | 123.8 | -111.8 | 113 |
| 2025-Q4* | 2026-03-23 | 87.8 | 26.8 | 18.5 | 0.88*≈ | 17.7 | 128.7° | -115.2 | 112 |
| 2025-Q3* | 2025-11-12 | 75.3 | 15 | 8.6 | 0.14 | 15.8 | 121 | -105.9 | 111 |
| 2025-Q2* | 2025-08-07 | 80.6 | 18.5 | 11.9 | 0.56 | 9.6 | 112.3 | – | 10 |
| 2025-Q1* | 2025-05-12 | 68.2 | 15.8 | 9.8 | 0.16 | 2.1 | 118.1 | -99.5 | 109 |
| 2024-Q4* | 2025-06-05 | 80.4 | 14.4 | 9.3 | 0.44*≈ | 20 | 118.2° | -97.9 | 8 |
| 2024-Q3* | 2024-11-18 | 70.1 | 15.4 | 5.4~ | 0.09 | 24.7 | 97.6° | -76.1 | 15 |
| 2024-Q2* | 2025-08-07 | 77.8 | 17 | 9.9~ | 0.46 | 8.2 | 76.6° | -53.1 | 10 |
| 2024-Q1* | 2024-07-15 | 67.6 | 14.2EBIT | 8.7~ | 0.42*≈ | -0.2 | 66.3 | -41.2 | 6 |
| 2023-Q4* | 2024-03-19 | 62.2 | 11.8 | 5.7 | 0.27*≈ | 7.7 | 68° | -41.6~ | 1 |
| 2023-Q3* | 2024-11-18 | 65.9 | 15.1 | 9.6~ | 0.46 | 1.6 | 88.4 | -50.2 | 115 |
| 2023-Q2* | 2023-09-19 | 60 | 12 | 6.3 | 0.30*≈ | 0.4 | 77.1 | -47.8 | 3 |
| 2023-Q1* | 2023-09-19 | 57.9 | 9.4EBIT | 4.8 | 0.23 | -1.7 | 79.8 | -54.4 | 103 |
* derived: values with formula provenance (hover); Q4 = FY − 9M · H2 = FY − H1 · EPS via implied shares · net debt = financial debt − cash · FCF = OCF − |capex|.
Columns not reported in this reporting cadence are hidden: Op. income (adj.), EBITDA (adj.), EPS adj. (not reported in any source for these periods).
Advertisement
Balance Sheet & Cash Flow (€m)#
Point-in-time balance sheet items (e.g. cash, financial debt) and cash flow items (operating cash flow, investments/capex) per fiscal year, half-year and quarter. All values are extracted automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original. Methodology
Fiscal years
Amounts in €m · as reported
| Period | Published | Cash | Debt | Net Debt | D&A | OCF | Capex | FCF | Source |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | 2026-03-23 | 128.7° | 13.5 | -115.2 | – | 58.4° | 13.2 | 45.2 | 112 |
| FY2024 | 2025-06-05 | 118.2° | 20.3 | -97.9 | 0.1 | 66.6° | 13.8 | 52.8 | 8 |
| FY2023 | 2024-03-19 | 68° | 26.4~ | -41.6~ | 0.5 | 47.4° | 26.3 | 21.1 | 1 |
Quarters
Amounts in €m · as reported
| Period | Published | Cash | Debt | Net Debt | OCF | Capex | FCF | Source |
|---|---|---|---|---|---|---|---|---|
| 2026-Q2 | 2026-08-12 | 110.2 | 10.4 | -99.8 | 7.6 | 4.2 | 3.4 | 114 |
| 2026-Q1 | 2026-05-11 | 123.8 | 11.9 | -111.8 | 5.2 | 5.6 | -0.4 | 113 |
| 2025-Q4 | 2026-03-23 | 128.7° | 13.5 | -115.2 | 18.7 | 1.1 | 17.7 | 112 |
| 2025-Q3 | 2025-11-12 | 121 | 15 | -105.9 | 17.6 | 1.8 | 15.8 | 111 |
| 2025-Q2 | 2025-08-07 | 112.3 | – | – | 15.1 | 5.5 | 9.6 | 10 |
| 2025-Q1 | 2025-05-12 | 118.1 | 18.5 | -99.5 | 7 | 4.9 | 2.1 | 109 |
| 2024-Q4 | 2025-06-05 | 118.2° | 20.3 | -97.9 | 21.5 | 1.5 | 20 | 8 |
| 2024-Q3 | 2024-11-18 | 97.6° | 21.6 | -76.1 | 27.6 | 2.9 | 24.7 | 15 |
| 2024-Q2 | 2025-08-07 | 76.6° | 23.5 | -53.1 | 13.3 | 5.1 | 8.2 | 10 |
| 2024-Q1 | 2024-07-15 | 66.3 | 25.1 | -41.2 | 4.1 | 4.3 | -0.2 | 6 |
| 2023-Q4 | 2024-03-19 | 68° | 26.4~ | -41.6~ | 16.8 | 9 | 7.7 | 1 |
| 2023-Q3 | 2024-11-18 | 88.4 | 38.2 | -50.2 | 8.5 | 6.8 | 1.6 | 115 |
| 2023-Q2 | 2023-09-19 | 77.1 | 29.3 | -47.8 | 6.8 | 6.4 | 0.4 | 3 |
| 2023-Q1 | 2023-09-19 | 79.8 | 25.5 | -54.4 | 2.3 | 4 | -1.7 | 103 |
Debt = long-term + current · Net debt = debt − cash · FCF = OCF − capex.
Advertisement
Revenue by Type (as of 2026-Q2 · EURm · 3/3)#
Revenue split by segment or product type, exactly as the company itself reports it. Methodology
| Segment | Since | Period | Basis | Revenue | Growth | Margin | Source |
|---|---|---|---|---|---|---|---|
| Medical | 2022-Q1 | 2026-Q1 | 3M | 41.5 | 20% | 58% | 13 |
| Isotope Products | 2022-Q1 | 2026-Q1 | 3M | 31.5 | -6% | 43% | 13 |
| Other | 2022-Q1 | FY2025 | 12M | 0 | – | – | 12 |
Advertisement
Products & M&A (20/60 active+recent)#
Product announcements from the reports; market launches, approvals, partnerships; with first mention (date) and source. Methodology
| Product/Line | Since | Status | Source |
|---|---|---|---|
| Medical isotope production facility in China | 2026-06 | Launched | 14 |
| Presentation at J.P. Morgan Healthcare Conference in San Francisco | 2026-03 | Planned | 13 |
| Increase in Actinium-225 production volume | 2026-03 | Launched | 13 |
| Board size reduction | 2026 | Planned | 12 |
| New laboratory building in Berlin | 2025-10 | Planned | 12 |
| GalliaPharm® 68Ge/68Ga Radionuclide Generator Market Approval Japan | 2025-09 | Launched | 11 |
| Share capital increase and stock split | 2025-08 | Launched | 12 |
| Illuccix® PSMA-PET Diagnostics | 2025-06 | Launched | 10 |
| GMP-compliant Ac-225 market launch | 2025-06 | Planned | 8 |
| Stock split and capital increase from company funds | 2025-06 | Planned | 10 |
| Theralugand® (Lu-177) national market approval in Europe | 2025-04 | Launched | 12 |
| Eckert & Ziegler CDMO Europe GmbH founding | 2025-03 | Launched | 11 |
| Dr. Gunnar Mann joins executive board | 2025-01 | Launched | 8 |
| Theralugan® EU approval national implementation | 2025 | Launched | 12 |
| Lu-177 (Theralugand®) for AtomVie Global Radiopharma | 2025 | Planned | 12 |
| Supply agreement with SK Biopharmaceuticals | 2025 | Stable | 12 |
| Illuccix® PSMA-PET diagnostic market approval in Germany | 2025 | Launched | 12 |
| Gallium-68 generator GalliaPharm® approval in Japan | 2025 | Launched | 12 |
| GalliaPharm® market approval in Japan | 2025 | Launched | 12 |
| Ac-225 Initiative (6x) | 2024 | Launched | 12 |
| New production facility in China (Jintan) first expansion stage completed | 2024-12 | Launched | 8 |
| Lu-177 radionuclide generator European approval | 2024-12 | Launched | 8 |
| Supply agreement with Ariceum Therapeutics | 2024-12 | Launched | 8 |
| Successful production start Actinium-225 | 2024-12 | Launched | 8 |
| Regulatory submission GalliaPharm with Japanese health authority | 2024-09 | Planned | 8 |
| Supply agreement with Glytherix | 2024-09 | Launched | 8 |
| Cooperation and license agreement Actinium-225 with Telix | 2024-09 | Launched | 8 |
| GalliaPharm EU Approval (x2) | 2024-09 | Launched | 8 |
| European contract manufacturer for ProstACT Global Phase III by Telix | 2024-09 | Launched | 8 |
| European approval Theralugand® Lutetium-177 Chloride | 2024-09 | Launched | 8 |
| Dresden-Rossendorf Operations Building Opening (x2) | 2024-09 | Launched | 8 |
| Phase III study with PentixaFor (2x) | 2024-06 | Launched | 8 |
| Opening Actinium-225 production facility in Prague | 2024-06 | Launched | 8 |
| Boston Radionuclide Theranostics Forum second edition | 2024-06 | Launched | 8 |
| Best Managed Companies Award by Deloitte Private | 2024-06 | Launched | 8 |
| Partnership with ArtBio for Lead-212 manufacturing | 2024-03 | Launched | 8 |
| MDR certification for prostate seeds | 2024-03 | Launched | 8 |
| MDR certification for prostate seeds by DEKRA Certification B.V. | 2024-03 | Launched | 6 |
| Expansion of Gallium-68 activities in Japan with Novartis | 2024-03 | Planned | 8 |
| AC-225 and LU-177 for Nucleus Radiopharma | 2024-03 | Launched | 8 |
| AC-225 supply agreement with Full-Life Technologies | 2024-03 | Launched | 8 |
| New diagnostic products by Tecnonuclear S.A. | 2024 | Planned | 5 |
| Market approvals new products GalliaPharm® | 2024 | Planned | 5 |
| GMP facility Berlin acceptance | 2024 | Planned | 5 |
| Actinium-225 planned for market | 2024 | Planned | 5 |
| Actinium-225 Production Braunschweig | 2024 | Planned | 5 |
| Production Facility Qi Kang Medical Technology Ltd. (Jintan, China) | 2023-06 | Planned | 4 |
| Clinical Study PentixaPharm Aldosterone Imaging (Monash Health, Melbourne) | 2023-06 | Launched | 4 |
| Phase I/II Dose-Finding Study PentixaPharm | 2023-06 | Planned | 4 |
| PENTIXAFOR (Boclatixafotide) Phase II Study for Cardiovascular Indications | 2023-03 | Launched | 3 |
| Drug Master File for (177Lu)Lutetium Chloride Filed with FDA | 2023-03 | Launched | 3 |
| Environmental Permit Production Site Jintan China | 2023 | Launched | 5 |
| Pentixather Phase I/II Study University Hospital Essen | 2023 | Launched | 5 |
| Pentixapharm CXCR4 Study Primary Hyperaldosteronism | 2023 | Launched | 5 |
| PENTIXAFOR Phase II Cardiovascular Indication University Hospital Lausanne | 2023 | Launched | 5 |
| Supply Agreement Lutetium-177 Point Biopharma | 2023 | Launched | 5 |
| Supply Agreement Lutetium-177 Ablaze Pharmaceuticals | 2023 | Launched | 5 |
| Manufacturing Authorization Lutetium-177 (2x) | 2023 | Launched | 4 |
| Drug Master File (DMF) Type II Lutetium-177 FDA | 2023 | Launched | 5 |
| 10-Year Supply Agreement Lutetium-177 with Major Pharmaceutical Company | 2023 | Launched | 5 |
Advertisement
M&A (32)#
All recorded acquisitions (purchases) and divestitures/exits with date, short description and source; deliberately including smaller transactions that summaries often miss. Methodology
Acquisitions · 24Divestitures/exits · 7older: 1 (in the table)
Acquisitions
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| Cooperation with Molecular Partners on Radio-DARPin Therapeutics | 2026-03 | Completed | 13 |
| Manufacturing Agreement with Pentixapharm for Y90-PentixaTher (2x) | 2025-06 | Completed | 12 |
| Partnership with Bicycle Therapeutics (2x) | 2025-03 | Completed | 12 |
| Lutetium-177 supply agreement AtomVie Global | 2025-03 | Completed | 9 |
| Ac-225 license agreement with Qi Kang Medical (JV with DC Pharma) (2x) | 2025-03 | Completed | 12 |
| Ac-225 for GlyTherix Ltd. (2x) | 2025-03 | Completed | 12 |
| Ac-225 for Actinium Pharmaceuticals (2x) | 2025-03 | Completed | 12 |
| Long-term collaboration with Czech Ústav jaderné fyziky (UJF) for Ac-225 production | 2025 | Completed | 12 |
| ART-101 framework agreement with Archeus Technologies (2x) | 2025 | Completed | 11 |
| Ac-225 Cyclotron Technology Cooperation Agreement with Telix | 2024-11 | Completed | 15 |
| Telix Pharmaceuticals ProstACT GLOBAL Phase III Supply Agreement | 2024-09 | Completed | 15 |
| Acquisition of target discovery unit of Glycotope GmbH by Pentixapharm AG | 2024-07 | Completed | 7 |
| Partnership with Novartis Pharma K.K. for Gallium-68 labeled diagnostics in Japan | 2024-03 | Completed | 6 |
| Supply agreement with Nucleus Radiopharma for Lutetium-177 and Actinium-225 | 2024-03 | Completed | 6 |
| Conversion to Societas Europaea (SE) | 2024-03 | Completed | 8 |
| Joint venture with DongCheng Pharma for Qi Kang Medical Technology | 2023-11 | Completed | 5 |
| No-carrier-added Lutetium-177 supply agreement with Point BioPharma | 2023-09 | Completed | 2 |
| Actinium-225 supply agreement with POINT Biopharma Global Inc. | 2023-06 | Completed | 4 |
| Tecnonuclear SA, Argentina - residual payment | 2023-01 | Completed | 3 |
| Actinium-225 reservation agreement PharmaLogic (2x) | 2023 | Completed | 2 |
| Long-term collaboration with UJF for Ac-225 production (2x) | 2023 | Completed | 8 |
| Cooperation with Reflexion Medical and Telix Pharmaceuticals (2x) | 2023 | Completed | 2 |
| Joint venture with Atom Mines LLC for Ytterbium-176 production | 2023 | Completed | 5 |
| Joint venture DongCheng Pharma (DC Pharma) China | 2023 | Completed | 5 |
| Tecnonuclear S.A. acquisition (SPECT diagnostics) | 2022 | Completed | 5 |
Divestitures / exits
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| Sale of remaining stake in BEBIG Medical GmbH | 2024-06 | Divested | 7 |
| Pentixapharm AG spin-off (6x) | 2024 | Divested | 8 |
| BEBIG Medical GmbH disposal of remaining shares | 2024 | Divested | 12 |
| Qi Kang Medical Technology deconsolidation | 2023-12 | Divested | 5 |
| Spin-off of clinical assets (Pentixapharm AG and Myelo Therapeutics GmbH) | 2023-12 | Divested | 6 |
| Myelo Therapeutics GmbH sale to Pentixapharm AG | 2023-09 | Divested | 5 |
| Sale of Wolf-Medizintechnik GmbH and HDR business | 2023-03 | Divested | 3 |
Advertisement
Risks (49 since the annual report of 2026-03-23, 124 tracked in total)#
Risk factors the company itself names in its reports, merged by topic across periods, with category, first and last mention and source. Methodology
| Risk | Category | First reported | Last reported |
|---|---|---|---|
| International trade and sanctions policy as well as the conflict in the Middle East give rise to heightened uncertainty | Geopolitics | 2026-Q2 2026-08-12 14 | 2026-Q2 2026-08-12 14 |
| Hedging structure for USD cash flows limits upside potential upon appreciation of the US dollar | Macro | 2026-Q1 2026-05-11 13 | 2026-Q2 2026-08-12 14 |
| Inflation loss under IAS 29 in Argentina reduces to EUR 0.972 million | Financial | 2023-Q3 2023-11-14 2 | FY2025 2026-03-23 12 |
| Higher risk from cost increases in the disposal of radioactive waste; provisions account for inflation-driven cost increases | Financial | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
| The ten largest customers account for approximately 27% of total output; risk of demand reduction | Customers | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
| Various contingent liabilities exist for guarantees and letters of comfort for subsidiaries | Legal | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
| Action by private individuals against the State of Lower Saxony seeking revocation of the handling permit at the Braunschweig site; a material portion of operations affected | Legal | FY2023 2024-03-19 5 | FY2025 2026-03-23 12 |
| Convertible bond of Pentixapharm Holding AG with maximum cash outflows of EUR 9.0 million up to 31 December 2026 | Legal | 2025-Q3 2025-11-12 11 | FY2025 2026-03-23 12 |
| Pentixapharm Holding AG Wandelanleihe; maximaler Mittelabfluss bis längstens 31. Dezember 2026 | Legal | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
| Dependence on disposal options; closure or delayed opening of disposal facilities may lead to cost increases | Regulatory | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
| Market entry barriers arising from regulatory approval requirements; operating licences required from LAGeSo, TÜV Nord, BfArM, FDA, NRC | Regulatory | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
| Obligations for the removal of radioactive residual materials with provisions of EUR 43.5 million (decommissioning and disposal) | Regulatory | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
| Security deposit for radioactive substances ordered pursuant to the Radiation Protection Act (EUR 0.9 million) | Regulatory | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
| Cyberattack in fiscal year 2025 with effects on ongoing operations and the annual financial statements | Technology | 2025-Q1 2025-05-12 9 | FY2025 2026-03-23 12 |
| Cyberangriff Anfang 2025 führte zu Infrastruktur-Wiederherstellungskosten | Technology | FY2023 2024-03-19 5 | FY2025 2026-03-23 12 |
| Convertible bond of Pentixapharm Holding AG with derivative accounting; recognised risk EUR 0.4 million | Legal | 2025-Q2 2025-08-07 10 | 2025-Q2 2025-08-07 10 |
| Veränderungen der Materialkosten können Profitabilität beeinträchtigen | Financial | 2026-Q1 2026-05-11 13 | 2026-Q1 2026-05-11 13 |
| Geopolitische Entwicklungen im Nahen Osten führen zu erhöhter wirtschaftlicher Unsicherheit | Geopolitics | 2026-Q1 2026-05-11 13 | 2026-Q1 2026-05-11 13 |
| Possible effects of the war in Ukraine and international trade sanctions policy | Geopolitics | 2024-Q2 2024-07-15 6 | 2026-Q1 2026-05-11 13 |
| Cyberattack carried out in February 2025; no material impairments across segments; extensive information security measures implemented | Cyber | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
| Environmental and sustainability obligations pursuant to ESRS; treatment and disposal of radioactive materials | ESG | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
| An increase in the level of interest rates may lead to a decline in fair values; impairment requirements at group level possible | Financial | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
| The economic success of the medical divisions depends on cost reimbursement for applications | Financial | FY2023 2024-03-19 5 | FY2025 2026-03-23 12 |
| General risk of list price increases by suppliers; countermeasures through price negotiations and strategic procurement decisions | Financial | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
| Ausreichende finanzielle Mittel vorhanden; Nettoliquidität zum Jahresende stabil | Financial | FY2024 2025-06-05 8 | FY2025 2026-03-23 12 |
| Mehrsprachige Operationen mit Wechselkursrisiken | Financial | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
| Loan liabilities partially at fixed rate, partially at variable rate with interest rate cap | Financial | FY2024 2025-06-05 8 | FY2025 2026-03-23 12 |
| Eckert & Ziegler exposed primarily on the procurement side; deliveries from Russia continuing; alternative suppliers available for most radioisotopes | Geopolitics | 2024-Q2 2024-09-09 7 | FY2025 2026-03-23 12 |
| Geopolitical tensions in the Middle East and western Pacific region could increase trade restrictions; the Group sees no undue risk | Geopolitics | FY2024 2025-06-05 8 | FY2025 2026-03-23 12 |
| Credit checks for new customers; deliveries partially secured by advance payments, guarantees or letters of credit | Customers | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
| Revenue concentrated in the United States at EUR 168.6 million | Customers | FY2023 2024-03-19 5 | FY2025 2026-03-23 12 |
| Risk of supply shortages and production outages; mitigated by inventory holdings and alternative sources of supply | Supply chain | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
| Business operations depend on the availability of radioactive materials | Supply chain | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
| Lieferketten-Diskussionen in Radiopharmazie-Branche als identifiziertes Risiko | Supply chain | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
| Highly specialised radionuclides and components require secure supply chains; qualification of alternative suppliers and processes necessary | Supply chain | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
| USD-Abwertung belastet Ergebnisse, EUR-Stärke vermindert Finanzmittelbestand | Macro | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
| Potential impact of tariffs on business development | Macro | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
| Andauernde Zolldiskussionen und Handelsembargos beeinflussen Geschäftstätigkeit | Market | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
| Exposure to USD, Brazilian Real and Argentine Peso; offset by global production network | Market | FY2023 2024-03-19 5 | FY2025 2026-03-23 12 |
| Abhängigkeit von spezialisierten Mitarbeitern; freiwerdende Positionen teilweise nur verzögert besetzbar | People | FY2023 2024-03-19 5 | FY2025 2026-03-23 12 |
| Spezialisierte Fachkräfte in Radioisototpenindustrie erforderlich | People | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
| Requirement for special regulatory permits for manufacturing and shipment; risk of regulatory changes; close cooperation with authorities | Regulatory | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
| Changes in technology and products for cancer treatment and nuclear medicine imaging influence state regulations and healthcare frameworks | Regulatory | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
| Handling permit required; withdrawal possible in the event of non-compliance with regulations | Regulatory | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
| Entwicklungsprojekte können aufgrund schnellerer Marktentwicklungen oder falscher Zielausrichtung erfolglos sein | Technology | FY2023 2024-03-19 5 | FY2025 2026-03-23 12 |
| Produkct liability risks aus Radioaktivität; strengen Qualitätskriterien unterworfen; ISO-zertifizierung; regelmäßige Schulungen zu Arbeitssicherheit und Strahlenschutz | Technology | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
| Risk that improved procedures by competitors could affect key markets; diversification across multiple business segments provides protection | Competition | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
| Wenige Anbieter in internationalen Märkten; Eckert & Ziegler hat keine direkten Wettbewerber mit vergleichbarem Produktportfolio, aber potenzielle Konkurrenz in speziellen Marktnischen | Competition | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
| Market characterised by rapid technological advancement and continuously new scientific discoveries | Competition | FY2025 2026-03-23 12 | FY2025 2026-03-23 12 |
Advertisement
Reported KPIs (as disclosed) (85)#
Figures the company discloses itself in addition to the standard financials; order intake, recurring revenue, user or unit counts, adjusted measures. Methodology
Company-specific KPIs verbatim from the filings (English, as disclosed; not normalised). Balance-sheet and boilerplate items filtered.
| Date | Period | KPI | Value / change | Source |
|---|---|---|---|---|
| 2026-08-12 | 2026-Q2 | Pre-tax profit margin | 22 | 14 |
| 2026-08-12 | 2026-Q2 | Equity ratio | 57 | 14 |
| 2026-05-11 | 2026-Q1 | Pre-tax profit margin | 21 | 13 |
| 2026-05-11 | 2026-Q1 | Equity ratio | 56,5 | 13 |
| 2026-05-11 | 2026-Q1 | Gross margin Medical | 58 | 13 |
| 2026-05-11 | 2026-Q1 | Gross margin Isotope Products | 43 | 13 |
| 2026-03-23 | FY2025 | net debt | -114.236 Mio. € | 12 |
| 2026-03-23 | FY2025 | Tax rate Medical | 23 | 12 |
| 2026-03-23 | FY2025 | Tax rate Isotope Products | 19 | 12 |
| 2026-03-23 | FY2025 | Tax rate | 32% | 12 |
| 2026-03-23 | FY2025 | Net financial position | 115,2 | 12 |
| 2026-03-23 | FY2025 | Share of women | 31 | 12 |
| 2026-03-23 | FY2025 | Staff turnover rate | 9 | 12 |
| 2026-03-23 | FY2025 | Equity ratio | 55% | 12 |
| 2026-03-23 | FY2025 | Equity | 253,4 Mio. € | 12 |
| 2026-03-23 | FY2025 | EBITDA | 90,8 (EUR thousands) | 12 |
| 2026-03-23 | FY2025 | Adjusted EBIT margin | 25% | 12 |
| 2026-03-23 | FY2025 | EBIT margin | 24% | 12 |
| 2026-03-23 | FY2025 | Average age | 41 | 12 |
| 2026-03-23 | FY2025 | Weighted average shares outstanding | 62,6 | 12 |
| 2026-03-23 | FY2025 | Dividend | 0,22 | 12 |
| 2026-03-23 | FY2025 | Book value per share | 4,05 | 12 |
| 2026-03-23 | FY2025 | Gross margin Medical | 67 | 12 |
| 2026-03-23 | FY2025 | Gross margin Isotope Products | 40 | 12 |
| 2026-03-23 | FY2025 | Total assets | 457,9 Mio. € | 12 |
| 2026-03-23 | FY2025 | Employees year-end | 1.116 | 12 |
| 2026-03-23 | FY2025 | Employees average | 1.105 | 12 |
| 2025-11-12 | 2025-Q3 | Pre-tax profit margin (prior year) | 20 | 11 |
| 2025-11-12 | 2025-Q3 | Pre-tax profit margin | 21 | 11 |
| 2025-11-12 | 2025-Q3 | Employees (31 December 2024) | 1.143 | 11 |
| 2025-11-12 | 2025-Q3 | Employees (30 September 2025) | 1.112 | 11 |
| 2025-11-12 | 2025-Q3 | Equity ratio | 51.6 | 11 |
| 2025-08-07 | 2025-Q2 | Employees | 1.098 | 10 |
| 2025-05-12 | 2025-Q1 | Pre-tax profit margin | 22.0 | 9 |
| 2025-05-12 | 2025-Q1 | Equity ratio | 51.6 | 9 |
| 2025-06-05 | FY2024 | Net liquidity | 98,135 Mio. € | 8 |
| 2025-06-05 | FY2024 | Tax rate | 30% | 8 |
| 2025-06-05 | FY2024 | Net financial position | 98,0 | 8 |
| 2025-06-05 | FY2024 | Equity ratio | 50% | 8 |
| 2025-06-05 | FY2024 | EBIT margin | 20% | 8 |
| 2025-06-05 | FY2024 | Book value per share | 10,72 € | 8 |
| 2025-06-05 | FY2024 | Employees year-end | 1.085 | 8 |
| 2025-06-05 | FY2024 | Employees annual average | 1.091 | 8 |
| 2024-11-18 | 2024-Q3 | Employees | 1.143 | 15 |
| 2024-09-09 | 2024-Q2 | Pre-tax profit margin | 20 | 7 |
| 2024-09-09 | 2024-Q2 | Employees end of period | 1.085 | 7 |
| 2024-07-15 | 2024-Q2 | Pre-tax profit margin | 20 | 6 |
| 2024-07-15 | 2024-Q2 | Employees end of period | 1.072 | 6 |
| 2024-07-15 | 2024-Q2 | Equity ratio | 51,9 | 6 |
| 2024-03-19 | FY2023 | Revenue per employee | 185 Tsd. € | 5 |
| 2024-03-19 | FY2023 | Tax rate | 27% | 5 |
| 2024-03-19 | FY2023 | Radiopharmaceuticals revenue | 126 Mio. € | 5 |
| 2024-03-19 | FY2023 | Number of employees | 1.095 | 5 |
| 2024-03-19 | FY2023 | Employees year-end | 1.075 | 5 |
| 2024-03-19 | FY2023 | Equity ratio | 51% | 5 |
| 2024-03-19 | FY2023 | Equity | 222,2 | 5 |
| 2024-03-19 | FY2023 | EBIT margin | 18% | 5 |
| 2024-03-19 | FY2023 | Weighted average shares outstanding | 20,8 | 5 |
| 2024-03-19 | FY2023 | Dividend | 0,05 | 5 |
| 2024-03-19 | FY2023 | Book value per share (31 Dec) | 10,7 | 5 |
| 2024-03-19 | FY2023 | Total assets | 439,4 | 5 |
| 2024-03-19 | FY2023 | Employees annual average | 1.035 | 5 |
| 2024-03-19 | FY2023 | Employees at year-end | 1.075 | 5 |
| 2024-03-19 | FY2023 | Average employees during the year | 1.035 | 5 |
| 2023-11-14 | 2023-Q3 | Pre-tax profit margin | 16 | 2 |
| 2023-11-14 | 2023-Q3 | Employees end of period | 1.062 | 2 |
| 2023-11-14 | 2023-Q3 | EBT | 30.237 (in thousands) | 2 |
| 2023-11-14 | 2023-Q3 | EBIT | 32.445 (EUR in thousands) | 2 |
| 2023-11-14 | 2023-Q3 | Depreciation on fixed assets | 9,2 | 2 |
| 2023-09-19 | 2023-Q2 | Net surplus | 4,7 Mio. € | 3 |
| 2023-09-19 | 2023-Q2 | Pre-tax profit margin | 14 | 3 |
| 2023-09-19 | 2023-Q2 | Employees end of period | 1.008 | 3 |
| 2023-09-19 | 2023-Q2 | Group result before non-controlling interests | 4,8 Mio. € | 3 |
| 2023-09-19 | 2023-Q2 | Equity ratio | 52 | 3 |
| 2023-09-19 | 2023-Q2 | EBT | 7,8 Mio. € | 3 |
| 2023-09-19 | 2023-Q2 | EBIT | 8,6 Mio. € | 3 |
| 2023-09-19 | 2023-Q2 | Treasury shares held | 360.006 | 3 |
| 2023-09-19 | 2023-Q2 | Share of share capital (treasury shares) | 1,70 | 3 |
| 2023-09-19 | 2023-Q2 | Depreciation on fixed assets | 2,9 Mio. € | 3 |
| 2023-08-10 | 2023-Q2 | Pre-tax return on sales prior year restated | 21 | 4 |
| 2023-08-10 | 2023-Q2 | Pre-tax return on sales prior year | 22 | 4 |
| 2023-08-10 | 2023-Q2 | Pre-tax profit margin | 15 | 4 |
| 2023-08-10 | 2023-Q2 | Employees at end of period prior year | 976 | 4 |
| 2023-08-10 | 2023-Q2 | Employees end of period | 1.036 | 4 |
| 2023-08-10 | 2023-Q2 | Equity ratio | 49 | 4 |
Advertisement
Guidance Tracking (latest per metric/period · 6/12)#
All management forecasts (guidance) and their later outcome. Methodology
Actuals: revenue in €m
| For period | Guided on | Metric | Guided | Actual | Verdict | Direction | Source |
|---|---|---|---|---|---|---|---|
| FY2026 | 2026-08-12 | Revenue | 320 | – | pending | raised | 14 |
| FY2026 | 2026-08-12 | EBITDA (adjusted) | 80 | – | pending | raised | 14 |
| FY2025 | 2025-11-12 | Revenue | ~300 | 312 | beat | raised | 11 |
| FY2025 | 2025-11-12 | EBIT | ~65 | – | – | confirmed | 11 |
| FY2025 | 2025-06-05 | EBIT (adjusted) | 65 | – | – | initiated | 8 |
| FY2025 | 2025-05-12 | EBITDA (adjusted) | 70 | – | – | confirmed | 10 |
| FY2024 | 2024-11-18 | Revenue | 290 | 295.9 | beat | cut | 15 |
| FY2024 | 2024-11-18 | Operating Income | 62 | – | – | confirmed | 15 |
| FY2024 | 2024-09-09 | EBIT | 70 | 61.1 | miss | raised | 7 |
| FY2024 | 2024-07-15 | EBITDA (adjusted) | 60 | – | – | confirmed | 6 |
| FY2023 | 2023-08-10 | Revenue | 230 | 246.1 | beat | confirmed | 2 |
| FY2023 | 2023-08-10 | net_income | 25 | – | – | confirmed | 2 |
Advertisement
Development#
A condensed summary per reporting period as running text: what changed operationally, which drivers management names, how earnings and cash flow developed. Methodology
FY2026
In the first half of fiscal year 2026, Eckert & Ziegler recorded Q1 revenue of 72.9 Mio. €, up 7% year-on-year 13, with half-year revenue reaching 149.3 Mio. € against a prior-year level of 148.8 Mio. € 14. Half-year group net income rose 4.5% to 22.4 Mio. € 14, supported by strong growth in Lutetium-177 revenues, which more than tripled, and Contract Manufacturing & Development revenues, which nearly doubled 14. The Medical segment was the primary growth driver in Q1, posting revenue up 20.7% year-on-year and a gross margin improvement of 2 percentage points to 58% 13. Half-year operating cash flow declined to 12.8 Mio. €, primarily due to the absence of a prior-year payment from the Qi Kang Medical joint venture, excluding that base effect the decline was described as the main driver 14. Strategically, the company transferred Actinium-225 production volume to high-volume scale 13 and opened a production facility for medical isotopes in Changzhou/Jintan, China with partner DongCheng Pharma 14.
FY2025
Eckert & Ziegler recorded full-year 2025 revenue of 312 million euros, up 5% year on year despite a cyberattack in February 2025 that caused temporary delivery delays 12. Adjusted EBIT rose 18% to 77.7 million euros and the EBIT margin expanded from 20% to 24% 12. Net income of 48.8 million euros was up 47% versus the prior year, with diluted EPS of 0.78 12. The net cash position improved 18% to 115.2 million euros and the equity ratio rose from 50% to 55% 12. Key milestones included the scaling of Actinium-225 production in the Czech Republic, the spin-off of the Pentixapharm group in October 2025, and new regulatory approvals for GalliaPharm® in Japan and Illuccix® in Germany 12.
FY2024
Eckert & Ziegler SE achieved full-year 2024 revenue of 295.9 million EUR, a new company record up 20% year-on-year, with demand for radiopharmaceutical products cited as the primary growth driver 8. Operating income reached 61.1 million EUR for the full year; net income attributable to shareholders was 33.3 million EUR, up 27% year-on-year 8. Radiopharmaceutical sales grew 37% to 81 million EUR across segments, and year-end cash amounted to 118.2 million EUR 8. The spin-off of Pentixapharm AG became legally effective on 2 October 2024, refocusing the group on its radioisotope core business, while the Ac-225 production facility in the Czech Republic recorded its first production in December 2024 8.
FY2023
Eckert & Ziegler SE posted record group revenue of 246.1 million euros in fiscal 2023, up 11% year on year, with both the Isotope Products and Medical segments contributing to growth 5. EBIT reached 45.5 million euros, declining 3% as the EBIT margin fell from 21% in 2022 to 18% in 2023, reflecting higher operating costs that outpaced revenue gains 5. Net income fell 10% to 26.3 million euros (1.26 per share), weighed by unplanned financial charges and currency losses, while operating cash flow rose 19% to 47.4 million euros 5. The year was marked by a strategic refocusing on isotope production and distribution: the company completed its conversion to a European SE, installed a new management board under CEO Dr. Harald Hasselmann, and resolved to spin off up to 80% of clinical subsidiary Pentixapharm AG, which was classified as a discontinued operation under IFRS 5 5. Multiple long-term supply agreements for carrier-free lutetium-177 and actinium-225 were signed, GMP manufacturing permits for Lu-177 were obtained at two sites, and the annual dividend was reduced to €0.05 per share from €0.50 in the prior year 5.
Advertisement
Glossary#
- Revenue: Revenue from contracts with customers, net of sales deductions, as the company itself reports it; not total output, gross revenue, GMV or order intake.
- Op. income: The operating line of the income statement; EBIT only as a marked fallback, never pre-tax or ordinary income.
- Net income: Net income attributable to the shareholders of the parent, after discontinued operations; not the result including minority interests, not comprehensive income.
- EPS: Diluted earnings per share attributable to the shareholders of the parent; a printed figure always beats a calculated one, calculated values are marked.
- FCF: Free cash flow = operating cash flow minus capital expenditure on property, plant and equipment; the company's own free cash flow figure is shown separately.
- OCF: Cash flow from operating activities as reported; IFRS companies may show interest paid in financing cash flow, so the figure is not always comparable.
- Cash: Cash and cash equivalents, without securities unless the company reports them as part of the position.
- Net Debt: Net debt = financial debt excluding lease liabilities minus cash at the same reporting date; the company's own net position may differ.
- *: derived, the formula is in the hover
- ≈: calculated, approximation
- ~: uncertain; the value stays visible, verdicts do not use it
- °: repaired by a targeted query against the document, or curated with documentary evidence
- EBIT: EBIT as a fallback: the income statement carries no operating line
- basic: basic earnings per share as a fallback when diluted is missing
Advertisement
Sources: quarterly reports, annual reports and investor relations documents#
All original documents NadirAlpha used for this report, with type (quarterly report, half-year report, annual report, earnings release), publication date and a direct link to the filing (EDINET/SEC/IR). Methodology
29 documents · 2023 to 2026 · IR
| # | Document type | Published | Link |
|---|---|---|---|
| #16 | IR-Quarter quarterly report | – | Open |
| #4 / #104 | IR-Quarter quarterly report | 2023-08-10 | Open |
| #17 | IR-Half half-year report | 2023-08-10 | Open |
| #3 / #103 | IR-Quarter quarterly report | 2023-09-19 | Open |
| #2 / #102 | IR-Quarter quarterly report | 2023-11-14 | Open |
| #18 | IR-Quarter quarterly report | 2023-11-14 | Open |
| #1 | IR-Report report | 2024-03-19 | Open |
| #5 / #105 | IR-Annual annual report | 2024-03-19 | Open |
| #19 / #119 | IR-Annual annual report | 2024-03-19 | Open |
| #22 | IR-Quarter quarterly report | 2024-06-26 | Open |
| #6 / #106 | IR-Quarter quarterly report | 2024-07-15 | Open |
| #7 / #107 | IR-Quarter quarterly report | 2024-09-09 | Open |
| #20 | IR-Quarter quarterly report | 2024-09-18 | Open |
| #21 | IR-Half half-year report | 2024-11-11 | Open |
| #15 / #115 | IR-Quarter quarterly report | 2024-11-18 | Open |
| #9 / #109 | IR-Quarter quarterly report | 2025-05-12 | Open |
| #24 | IR-Quarter quarterly report | 2025-05-12 | Open |
| #8 / #108 | IR-Annual annual report | 2025-06-05 | Open |
| #23 | IR-Annual annual report | 2025-06-05 | Open |
| #10 / #110 | IR-Quarter quarterly report | 2025-08-07 | Open |
| #25 | IR-Half half-year report | 2025-08-28 | Open |
| #11 / #111 | IR-Quarter quarterly report | 2025-11-12 | Open |
| #26 | IR-Quarter quarterly report | 2025-11-12 | Open |
| #12 / #112 | IR-Annual annual report | 2026-03-23 | Open |
| #27 | IR-Annual annual report | 2026-03-23 | Open |
| #13 / #113 | IR-Quarter quarterly report | 2026-05-11 | Open |
| #28 | IR-Quarter quarterly report | 2026-05-11 | Open |
| #14 / #114 | IR-Quarter quarterly report | 2026-08-12 | Open |
| #29 | IR-Half half-year report | 2026-08-12 | Open |
FAQ#
Is there a management forecast (guidance) for FY2026?
Yes. Management has issued targets for FY2026, including Revenue. The guidance tracking chapter shows all targets and checks them against the actuals reported later; neutral, with no estimate of our own.
Which additional key figures does Eckert & Ziegler SE report?
As reported for Q2 2026: Equity ratio, Pre-tax profit margin. The chapter Reported KPIs lists every value with its source. Revenue is broken down by Medical, Isotope Products, Other.
Does Eckert & Ziegler SE pay a dividend?
The filings report on the dividend; most recent entry: dividends paid 0,22 (FY2025) (as reported, no assessment of our own). Details with source links are in the report chapters.
Where can I find the official investor relations documents of Eckert & Ziegler SE?
NadirAlpha links all 44 original filings used (IR documents) in the sources chapter: quarterly report, annual report, half-year report, each with type, publication date and a direct link; every figure in the report carries a source number.
More reports by NadirAlpha#
Recently updated
Same sector and country
Advertisement